Wednesday, July 8, 2026

Drug profile · INN

nesiritide

nesiritide (NATRECOR) is a atrial natriuretic peptide receptor a agonist. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 1
Pipeline programs 0
News articles 0
Drug details — nesiritide
US status
approved
Class
Route
INTRAVENOUS
Patents
1
Programs
0
Data quality
0.84

Quick answer

nesiritide (NATRECOR) is a atrial natriuretic peptide receptor a agonist. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN nesiritide
Brand NATRECOR
Mechanism Atrial natriuretic peptide receptor A agonist
Target Atrial natriuretic peptide receptor 1
Route INTRAVENOUS
Formulation FOR SOLUTION

Mechanism of action

Atrial natriuretic peptide receptor A agonist

Primary target: Atrial natriuretic peptide receptor 1

Approval history

Authority Status Date
FDA approved

Related patents

  1. US 8449872

    Polymer conjugates of nesiritide peptides

    Expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is nesiritide?

nesiritide (NATRECOR) is a atrial natriuretic peptide receptor a agonist. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for nesiritide?

NATRECOR is a marketed brand name for nesiritide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nesiritide?

nesiritide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.